Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Counterpoint: statins do reduce fatal events.

Sniderman AD, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD.

J Clin Lipidol. 2013 May-Jun;7(3):225-7; discussion 228. doi: 10.1016/j.jacl.2012.12.004. No abstract available.

PMID:
23725923
2.

[Anti-inflammatory effect of HMG-CoA reductase inhibitors].

Kitamoto S, Egashira K.

Nihon Rinsho. 2004 Jan;62(1):172-9. Review. Japanese.

PMID:
14737850
3.

The HMG-CoA reductase pathway, statins and angioprevention.

Feng C, Han A, Ye C, Xu R, Li M.

Semin Ophthalmol. 2006 Jan-Mar;21(1):29-35. Review.

PMID:
16517442
4.

Pleiotropic effects of HMG-CoA reductase inhibitors.

Bocan TM.

Curr Opin Investig Drugs. 2002 Sep;3(9):1312-7. Review.

PMID:
12498006
5.

Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes.

Chaiyakunapruk N, Boudreau D, Ramsey SD.

J Cardiovasc Risk. 2001 Jun;8(3):127-32. Review.

PMID:
11455843
6.

HMG-CoA reductase inhibitors and the kidney.

Campese VM, Hadaya B, Chiu J.

Curr Hypertens Rep. 2005 Oct;7(5):337-42. Review.

PMID:
16157074
7.
8.

Statins in dermatology.

Jowkar F, Namazi MR.

Int J Dermatol. 2010 Nov;49(11):1235-43. doi: 10.1111/j.1365-4632.2010.04579.x. Review.

PMID:
20964647
9.

Statins reduce cardiovascular events in primary and secondary prevention trials without causing an increase in carcinoma.

Aronow WS.

J Am Geriatr Soc. 2009 Oct;57(10):1942-3; author reply 1943-4. doi: 10.1111/j.1532-5415.2009.02456.x. No abstract available.

PMID:
19807799
10.

Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.

Fritz G, Henninger C, Huelsenbeck J.

Br Med Bull. 2011;97:17-26. doi: 10.1093/bmb/ldq044. Review.

PMID:
21252099
11.

[Safety profile of statins].

Prieto JC.

Rev Med Chil. 2001 Nov;129(11):1237-40. Spanish.

PMID:
11836874
12.

Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis.

Arnaud C, Veillard NR, Mach F.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Apr;5(2):127-34. Review.

PMID:
15853754
13.

Use of statins to reduce the risk of cardiovascular disease in adults.

Ford H.

Nurs Stand. 2013 May 29-Jun 4;27(39):48-56; quiz 58.

PMID:
23855160
14.

The use of statins in pediatrics: knowledge base, limitations, and future directions.

Belay B, Belamarich PF, Tom-Revzon C.

Pediatrics. 2007 Feb;119(2):370-80. Review.

PMID:
17272627
15.

Do statins reduce the risk of infection?

Golomb BA.

BMJ. 2011 Nov 29;343:d7134. doi: 10.1136/bmj.d7134. No abstract available.

PMID:
22127442
16.

[Statins in the management of dyslipidemias].

Scheen AJ.

Rev Prat. 2011 Oct;61(8):1120-6. French.

PMID:
22135981
17.

Pleiotropic effects of HMG-CoA reductase inhibitors.

Werner N, Nickenig G, Laufs U.

Basic Res Cardiol. 2002 Mar;97(2):105-16. Review.

PMID:
12002257
18.

Statins. Evidence of effectiveness in older patients.

Nash DT.

Geriatrics. 2003 May;58(5):35-6, 39-42. Review.

PMID:
12756679
19.

Statins and plaque stability.

Gomberg-Maitland M, Fuster V, Fayad ZA, Badimon JJ, Corti R.

J Cardiovasc Risk. 2003 Jun;10(3):161-7. Review.

PMID:
12775948
20.
Items per page

Supplemental Content

Support Center